MCM
NVCR icon

McKinley Capital Management’s NovoCure NVCR Stock Holding History

McKinley Capital Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-23,019
Closed -$771K – 288
2018
Q4 		$771K Buy
23,019
+2,790
+14% +$102K 0.06% 140
2018
Q3 		$1.06M Buy
+20,229
New +$805K 0.07% 134

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DCP
Darsana Capital Partners New York $4.7B AUM 50.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

McKinley Capital Management's NVCR Position: Q1 2019 in Review

McKinley Capital Management sold out of NovoCure (NVCR) in Q1 2019, closing a stake of 23,019 shares — an estimated $771K sold.

McKinley Capital Management first reported a position in NVCR in Q3 2018 and held it in 2 quarters. The position peaked at $1.06M in Q3 2018. 200 funds tracked by Wall St. Rank hold NVCR as of Q1 2019.

  • McKinley Capital Management reported no remaining NovoCure position as of Q1 2019 after selling out during the quarter.
  • McKinley Capital Management sold 23,019 NovoCure shares in Q1 2019, an estimated $771K.
  • McKinley Capital Management first reported a position in NovoCure in Q3 2018 and held it in 2 quarters.
  • McKinley Capital Management's NovoCure position peaked at $1.06M in Q3 2018.
  • 200 funds tracked by Wall St. Rank held NovoCure as of Q1 2019.

Based on McKinley Capital Management's 13F filing for Q1 2019, filed 2 May 2019.